Description: TG Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of innovative and medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The company is developing two advanced therapies targeting hematological malignancies. The TGTX-1101 (ublituximab) is a novel, third generation monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes, which is in clinical development for patients with relapsed and refractory non-Hodgkin's lymphoma. The TGR-1202 is an orally available PI3K delta inhibitor believed to be important in the proliferation and survival of B-lymphocytes. TG Therapeutics, Inc. is headquartered in New York, New York.
Home Page: www.tgtherapeutics.com
TGTX Technical Analysis
2 Gansevoort Street
New York,
NY
10014
United States
Phone:
212 554 4484
Officers
| Name | Title |
|---|---|
| Mr. Michael S. Weiss Esq. | Chairman, CEO & Pres |
| Mr. Sean A. Power CPA, CPA | CFO, Corp. Sec. & Treasurer |
| Jenna Bosco | Sr. VP of Corp. Communications |
| Mr. Adam Waldman | Chief Commercialization Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 10.8774 |
| Price-to-Sales TTM: | 249.2734 |
| IPO Date: | 1995-12-14 |
| Fiscal Year End: | December |
| Full Time Employees: | 186 |